|
|
|
|
| LEADER |
02603nam a2200385 4500 |
| 001 |
PPN231631154 |
| 003 |
http://www.sudoc.fr/231631154 |
| 005 |
20191008020900.0 |
| 010 |
|
|
|a 978-0-12-801076-1
|b rel.
|
| 073 |
|
1 |
|a 9780128010761
|
| 100 |
|
|
|a 20181113h20162016k y0frey0103 ba
|
| 101 |
0 |
|
|a eng
|
| 102 |
|
|
|a NL
|
| 105 |
|
|
|a a z 001yy
|
| 106 |
|
|
|a r
|
| 181 |
|
|
|6 z01
|c txt
|2 rdacontent
|
| 181 |
|
1 |
|6 z01
|a i#
|b xxxe##
|
| 182 |
|
|
|6 z01
|c n
|2 rdamedia
|
| 182 |
|
1 |
|6 z01
|a n
|
| 183 |
|
1 |
|6 z01
|a nga
|2 rdacarrier
|
| 200 |
1 |
|
|a Drug-Like Properties
|e concepts, Structure Design and Methods from ADME to Toxicity Optimization
|f Li Di, Edward H Kerns
|
| 205 |
|
|
|a Second edition
|
| 210 |
|
|
|a Amsterdam
|c Elsevier Science
|d cop. 2016
|
| 320 |
|
|
|a Références bibliographiques. Index
|
| 359 |
2 |
|
|a 1. Introduction 2. The Advantages of Good Drug-like Properties 3. Barriers to Drug Exposure in Living Systems 4. Rules for Rapid Property Profiling From Structure 5. Lipophilicity 6. pKa 7. Solubility 8. Permeability 9. Transporters 10. Blood-Brain Barrier 11. Metabolic Stability 12. Plasma Stability 13. Solution Stability 14. Plasma Protein Binding 15. Cytochrome P450 Inhibition 16. hERG Blocking 17. Toxicity 18. Integrity and Purity 19. Pharmacokinetics 20. Lead-like Compounds 21. Strategies for Integrating Drug-Like Properties Into Drug Discovery 22. Methods for Profiling Drug-like Properties: General Concepts 23. Lipophilicity Methods 24. pKa Methods 25. Solubility Methods 26. Permeability Methods 27. Transporter Methods 28. Blood-Brain Barrier Methods 29. Metabolic Stability Methods 30. Plasma Stability Methods 31. Solution Stability Methods 32. CYP Inhibition Methods 33. Plasma Protein Binding Methods 34. hERG Methods 35. Toxicity Methods 36. Integrity and Purity Methods 37. Pharmacokinetics Methods 38. Diagnosing and Improving Pharmacokinetic Performance 39. Prodrugs 40. Effects of Properties on Biological Assays 41. Formulation
|
| 452 |
|
| |
|0 195534360
|t Drug-Like Properties
|o concepts, Structure Design and Methods from ADME to Toxicity Optimization
|f Li Di, Edward H Kerns
|e 2nd edition
|c San Diego
|n Elsevier Science
|d 2015, cop. 2016
|y 978-0-12-801322-9
|
| 606 |
|
|
|3 PPN027797996
|a Chimie pharmaceutique
|2 rameau
|
| 606 |
|
|
|3 PPN035266422
|a Médicaments
|x Mise au point
|2 rameau
|
| 606 |
|
|
|3 PPN029408873
|a Médicaments
|x Relations structure-activité
|2 rameau
|
| 700 |
|
1 |
|3 PPN184613892
|a Di
|b Li
|4 070
|
| 701 |
|
1 |
|3 PPN124338534
|a Kerns
|b Edward Harvel
|4 070
|
| 801 |
|
3 |
|a FR
|b Abes
|c 20181113
|g AFNOR
|
| 979 |
|
|
|a SCI
|
| 930 |
|
|
|5 441092104:623358948
|b 441092104
|j u
|
| 998 |
|
|
|a 822389
|
Nantilus
